Ambryon Biosciences

High-fidelity Cas12Max, an engineered Cas12i-family nuclease (hfCas12Max)

High-fidelity engineered variant of Cas12Max, itself derived from the natural Cas12i ortholog xCas12i (a type V-I CRISPR nuclease). Three arginine substitutions in the PAM-interacting, REC, and RuvC domains reduce off-target cleavage while retaining on-target editing efficiency, with broad 5'-TN and 5'-TNN PAM recognition.

OriginEngineered from xCas12i via intermediate Cas12Max (N243R)
Cut Type5 Overhang
Pam SequenceTTN

Characteristics

Single-RuvC-domain type V-I nuclease that autonomously processes its own pre-crRNA and preferentially nicks the non-target DNA strand before cutting the target strand, characteristic of the Cas12i family. Carries N243R (PAM-interacting domain), E336R (REC domain), and D892R (RuvC domain) substitutions over parental xCas12i. Recognizes broad 5'-TN and 5'-TNN PAMs, including TTN, ATN, GTN, and CTN, and reaches an average 70% indel efficiency across TTR reporter loci in HEK293T cells, exceeding SpCas9, LbCas12a, and Ultra-AsCas12a tested under matched conditions. Shows reduced indel frequency at six identified off-target sites relative to the single-mutant Cas12Max while retaining comparable on-target activity.

Applications

Ex vivo TRAC knockout in human CD3+ T cells via ribonucleoprotein delivery, reaching approximately 90% editing with approximately 80% viability. In vivo liver editing via lipid-nanoparticle-delivered mRNA, reaching approximately 70% indel frequency at the murine Ttr locus at 0.3-0.5 mg/kg. Nuclease-dead fusions support adenine and cytosine base editing (dCas12Max-ABE, dCas12Max-CBE) in HEK293T cells.

Limitations

Requires a 5'-TTN-type PAM, though broader than most natural Cas12i orthologs. Reported in a single 2023 study; independent replication and long-term in vivo safety data are not yet available. Off-target reduction was benchmarked against a small panel of predicted sites rather than genome-wide profiling.

Sequence3,200 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Zhang et al. (2023). An engineered xCas12i with high activity, high specificity, and broad PAM range. Protein Cell — Zhang 2023 hfCas12MAX

Identifiers & revision